- Home
- ATHA vs LDWY Comparison
ATHA vs LDWY Comparison
Compare ATHA & LDWY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- LDWY
- Stock Information
- Founded
- ATHA 2011
- LDWY 1990
- Country
- ATHA United States
- LDWY United States
- Employees
- ATHA N/A
- LDWY N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- LDWY Advertising
- Sector
- ATHA Health Care
- LDWY Consumer Discretionary
- Exchange
- ATHA Nasdaq
- LDWY Nasdaq
- Market Cap
- ATHA 10.6M
- LDWY 9.2M
- IPO Year
- ATHA 2020
- LDWY 1991
- Fundamental
- Price
- ATHA $0.42
- LDWY $4.79
- Analyst Decision
- ATHA Buy
- LDWY
- Analyst Count
- ATHA 4
- LDWY 0
- Target Price
- ATHA $11.25
- LDWY N/A
- AVG Volume (30 Days)
- ATHA 239.8K
- LDWY 3.4K
- Earning Date
- ATHA 07-31-2025
- LDWY 08-18-2025
- Dividend Yield
- ATHA N/A
- LDWY N/A
- EPS Growth
- ATHA N/A
- LDWY N/A
- EPS
- ATHA N/A
- LDWY N/A
- Revenue
- ATHA N/A
- LDWY $42,183,000.00
- Revenue This Year
- ATHA N/A
- LDWY N/A
- Revenue Next Year
- ATHA N/A
- LDWY N/A
- P/E Ratio
- ATHA N/A
- LDWY N/A
- Revenue Growth
- ATHA N/A
- LDWY 425.12
- 52 Week Low
- ATHA $0.22
- LDWY $3.02
- 52 Week High
- ATHA $3.67
- LDWY $5.53
- Technical
- Relative Strength Index (RSI)
- ATHA 73.73
- LDWY 60.30
- Support Level
- ATHA $0.29
- LDWY $4.56
- Resistance Level
- ATHA $0.32
- LDWY $5.23
- Average True Range (ATR)
- ATHA 0.03
- LDWY 0.22
- MACD
- ATHA 0.01
- LDWY 0.00
- Stochastic Oscillator
- ATHA 78.16
- LDWY 89.52
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.